v3.25.2
Segment Disclosures (Tables)
6 Months Ended
Jun. 30, 2025
Segment Disclosures  
Schedule of significant expense categories regularly reviewed by the CODM

    

Three Months Ended June 30, 

    

Six Months Ended June 30, 

2025

2024

2025

2024

(in thousands)

 

  

 

  

 

  

 

  

Partnership revenue

$

667

$

628

$

1,399

$

1,125

Product revenue

 

169

 

150

 

305

 

273

Expenses:

Cost of product revenues

 

46

 

44

 

90

 

78

Non-clinical development costs

 

4,607

 

4,648

 

9,072

 

7,947

Clinical development costs

 

2,633

 

1,504

 

5,575

 

2,547

Personnel and consulting costs

 

7,002

 

5,913

 

13,666

 

11,407

Stock-based compensation

 

3,250

 

2,761

 

6,215

 

5,349

Depreciation expense

 

81

 

74

 

164

 

148

Other segment expenses(1)

 

2,544

 

2,716

 

5,170

 

5,283

Interest income (expense), net

 

36

 

(902)

 

(130)

 

(1,918)

Net Loss

$

(19,363)

$

(15,980)

$

(38,118)

$

(29,443)

1Other segment expenses primarily include general and administrative costs not presented in other line items.